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Abstract
The neuronal transporter GlyT2 is a polytopic, 12-transmembrane domain, plasma membrane glycoprotein involved in the
removal and recycling of synaptic glycine from inhibitory synapses. Mutations in the human GlyT2 gene (SLC6A5) that cause
deficient glycine transport or defective GlyT2 trafficking are the second most common cause of hyperekplexia or startle
disease. In this study we examined several aspects of GlyT2 biogenesis that involve the endoplasmic reticulum chaperone
calnexin (CNX). CNX binds transiently to an intermediate under-glycosylated transporter precursor and facilitates GlyT2
processing. In cells expressing GlyT2, transporter accumulation and transport activity were attenuated by siRNA-mediated
CNX knockdown and enhanced by CNX overexpression. GlyT2 binding to CNX was mediated by glycan and polypeptide-
based interactions as revealed by pharmacological approaches and the behavior of GlyT2 N-glycan-deficient mutants.
Moreover, transporter folding appeared to be stabilized by N-glycans. Co-expression of CNX and a fully non-glycosylated
mutant rescues glycine transport but not mutant surface expression. Hence, CNX discriminates between different
conformational states of GlyT2 displaying a lectin-independent chaperone activity. GlyT2 wild-type and mutant transporters
were finally degraded in the lysosome. Our findings provide further insight into GlyT2 biogenesis, and a useful framework
for the study of newly synthesized GlyT2 transporters bearing hyperekplexia mutations.
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Introduction
Glycine is the major inhibitory neurotransmitter in caudal areas
of the vertebrate central nervous system, participating in the motor
and sensory information processing involved in movement, vision
and audition [1,2]. Moreover, glycinergic inhibition also mod-
ulates nociceptive signaling [3]. The synaptic action of glycine is
terminated by its reuptake via specific plasma membrane
transporters (GLyTs), which perform high-affinity, active co-
transport coupled to the electrochemical gradient of Na+ and
dependent on Cl2 [4]. The neuronal GlyT2 transporter is
involved in the removal and recycling of synaptic glycine from
inhibitory synapses by supplying substrate to the low-affinity
vesicular transporter VIAAT (VGAT) [5–8]. Presynaptic glycine
taken up by GlyT2 has been demonstrated to be the sole source of
releasable transmitter at glycinergic synapses [9], and inactivation
of the GlyT2 gene in mice generates a complex postnatal
neuromotor phenotype that reproduces the symptoms of human
hyperekplexia [6].
Hyperekplexia or startle disease (OMIM 149400) is character-
ized by neonatal hypertonia and an exaggerated startle response to
trivial stimuli [10]. This disorder can lead to brain damage and/or
sudden infant death caused by apneic episodes. Genetic analysis of
hyperekplexia patients has identified mutations in the human
GlyT2 gene (SLC6A5) as the second most common cause of the
disease, after mutations affecting the glycine receptor and other
key proteins in glycinergic synapses [11,12]. A model of the 3-
dimensional structure of GlyT2 was recently developed [13,14]
using as a template the leucine transporter from Aequifex aeolicus
(LeuTAa), a prokaryotic homologue of the solute carrier 6 (SLC6)
family to which GlyT2 belongs [15]. This model provides an
explanation for the effects of selected missense mutations on Na+-
and glycine-binding residues crucial for transport [12,16–19]. The
majority of GlyT2 mutations are recessive and cause bi-allelic loss
of function due to the absence of the protein in the plasma
membrane or the generation of inactive transporters [12]. Only
one dominant mutation affecting GlyT2 intracellular trafficking
has been described to date (S510R), which is proposed to block the
arrival of the transporter to the plasma membrane [16]. However,
recently a dominantly inherited mutation that causes complex
alterations in transport function and that hinders the proper
expression of the transporter at the cell membrane was described
[18]. While the trafficking of GlyT2 to and from the plasma
membrane along the late secretory pathway has been studied
largely [20–22], similar analyses of the biogenesis of GlyT2 and its
trafficking along the early secretory pathway have not been
performed, despite the importance of these processes in the
physiology and pathologies of glycinergic neurotransmission.
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The synthesis of GlyT2, a polytopic plasma membrane protein,
begins with its co-translational translocation to the endoplasmic
reticulum (ER) [23]. The biogenesis of these proteins requires
interactions with ER chaperones, such as calnexin (CNX),
calreticulin (CRT), BiP (GRP78), and oxidoreductases like
ERp57 and PDI [24]. CNX is a type I integral membrane
protein responsible for the folding and quality control of newly-
synthesized glycoproteins [25]. The ER luminal domain of
calnexin is responsible for lectin-like activity and interaction with
nascent polypeptide chains [26]. Protein-protein interactions may
also mediate the interaction with CNX [27,28]. The second
extracellular loop (EL2) of GlyT2 contains 4 asparagines (N345,
N355, N360 and N366) that are N-glycosylated in the mature
protein. The N-glycosylation of GlyT2 is partially responsible for
its arrival to the plasma membrane, and its asymmetric
distribution in polarized cells [29]. In addition, oligomer assembly
of neurotransmitter transporters appears to be a prerequisite for
export to the plasma membrane and their asymmetric targeting to
the neuronal synapse [30].
Here, we confirm a role for CNX in GlyT2 biogenesis, and we
describe the kinetics and determinants of the GlyT2-CNX
interaction. Our data identify some of the key features of GlyT2
biogenesis in the early secretory pathway. These findings may help
to decipher the effects of hyperekplexia mutations on the plasma
membrane expression of newly synthesized GlyT2 transporters.
Figure 1. GlyT2 expression after a pulse-chased in culture cells. COS7 cells transfected with GlyT2 cDNA in pCDNA3 were pulse-labeled for
15 min with [35S]methionine/cysteine and chased for the times indicated in the conditions given in Material and Methods. The cells were then surface
biotinylated, lysed and the protein lysate was either immunoprecipitated with GlyT2 antibody (total transporter, A) or bound to streptavidin-agarose
and sequentially immunoprecipitated with GlyT2 antibody (biotinylated fraction, B). Proteins extracted from the beads were resolved in SDS-PAGE.
(A) Kinetics of GlyT2 expression. (B) Kinetics of GlyT2 plasma membrane expression in the same cells as in A. Lower panels: (A) densitometry of the
100 kDa and 75 kDa bands in the fluorograms. (B) Biotinylated bands are represented as a percentage of each of the lanes labeled in A. Bars
represent the S.E.M. (n = 3). (C) Cells were treated overnight with the vehicle alone (DMSO) or with 10 mg/ml tunicamycin, and then pulse-chased as
described above. (D, E) Immunoprecipitates were treated overnight with the vehicle alone (endoglycosidase buffer, -) or with the indicated
endoglycosidase (+) in denaturing conditions, and then resolved by SDS-PAGE as described in the Materials and Methods. The transporter proteins
(100 kDa, 75 kDa and 60 kDa) are indicated with arrowheads.
doi:10.1371/journal.pone.0063230.g001
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Materials and Methods
Cell Growth and Protein Expression
COS7 cells (American Type Culture Collection) were grown at
37uC and 5% CO2 in Dulbecco’s modified Eagle’s medium
supplemented with 10% fetal bovine serum. Transient expression
was achieved using NeofectinTM (MidAtlantic Biolabs), according
to the manufacturer’s protocol. Reproducible results were
obtained with 50–60% confluent cells on 60 mm or 6 well plates
using 5.5 mg and 2.5 mg of total DNA, respectively. Cells were
incubated for 48 h at 37uC until used. Transfection efficiency was
determined by co-transfecting the cDNAs with the pSV-b-
galactosidase plasmid (Promega) and measuring b-galactosidase
activity 24 h later after cell solubilization with 25 mM glycylgly-
cine pH 7.8, 0.5% Triton X-100, 1 mM DTT (100 ml/well). After
centrifugation (15,0006g) for 2 min, supernatants (15 ml) were
transferred to a 96 well plate together with 1 volume of assay
buffer (2 mM MgCl2, 120 mM NaPO4, 80 mM Na2HPO4,
100 mM b-mercaptoethanol and 1.33 mg/ml O-nitophenyl-b-
D-galactopyranoside) and incubated for 20 min at 37uC. Absor-
bance was measured at 420 nm in an ELISA Dynatech MR5000
and normalized to the protein concentration. Rat brain stem
primary neuronal cultures were performed as previously described
[29].
Plasmid Constructs
N-glycosylation mutants of rat GlyT2 were inserted into
a pCDNA3 vector either as described previously [31] or
constructed by site-directed mutagenesis using the QuikChange
kit (Stratagene) [32]. Two independent Escherichia coli colonies
Figure 2. GlyT2 co-immunoprecipitates with CNX. (A) Lysates of COS7 cells expressing GlyT2 were immunoprecipitated with anti-CNX (CNX),
anti-calreticulin (CRT) or no antibody (PAS) and then analyzed in Western blots (WB) to detect GlyT2 in the presence or absence (no addition) of
100 mg/ml of the GlyT2 fusion protein used as antigen to generate the rabbit GlyT2 antibody (GlyT2-GST) [30]. The input GlyT2 lane contains 10% of
the protein loaded for immunoprecipitation (IP). PAS: protein A sepharose (,45 kDa). (B) Rat brain stem primary neurons were immunoprecipitated
with anti-GlyT2 antibody made in rat [20] and then analyzed in WBs to detect the endogenous immunoprecipitated GlyT2 or CNX by using antibodies
made in rabbit. The input lanes contain 5% of the protein loaded for immunoprecipitation (IP). Arrowheads indicate GlyT2. PGS: protein G sepharose
(,17 kDa). (C) COS7 cells expressing GlyT2 were pulse-labeled for 15 min with [35S]methionine/cysteine, chased for the times indicated and
subjected to sequential immunoprecipitation with CNX and GlyT2 antibodies, as described in the Materials and Methods. Lower panel: densitometry
of the fluorograms.
doi:10.1371/journal.pone.0063230.g002
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carrying the mutant plasmids were characterized by DNA
sequencing and [3H]glycine transport activity. We sequenced the
complete coding region of each construct to verify that only the
desired mutation had been introduced. Mouse cDNA CNX clone
(IMAGE number 2582119) was purchased from Source Bio-
science Lifesciences.
Pulse and Chase
Cells cultured to 80–90% confluence in p60 or p100 plates were
incubated with methionine-free medium for 1 hour. The cells
were then pulse-labeled for 15 min with 0.25 mCi/ml [35S]me-
thionine/cysteine (Redivue Promix, Amersham) and chased for
varying periods in Dulbecco’s modified Eagle’s medium 10% fetal
calf serum containing 1 mM cycloheximide to quickly stop the
elongation of nascent polypeptide chains. Labeling was stopped by
the addition of ice-cold phosphate-buffered saline (PBS) containing
20 mM freshly prepared N-ethylmaleimide to prevent oxidation of
free sulfhydryl groups. Proteins were immunoprecipitated with
GlyT2 antibody [33] or sequentially with anti-CNX (Stressgen)
and anti-GlyT2 antibodies, as described below. Samples were
resolved in SDS-polyacrylamide gels (SDS-PAGE), fixed and
treated with Amplify fluorography reagent (Amersham). The gels
were dried and exposed for 4–12 days at 270uC, and the protein
bands were quantified after densitometry.
Carbohydrate Modification
Pulse-chased GlyT2 immunoprecipitates were digested with the
desired endoglycosidase (PNGase F, New England Biolabs; or
Endoglycosidase H or D, Roche) in a small volume of the
appropriate buffer, following the manufacturer’s instructions. For
tunicamycin treatment, GlyT2-expressing cells were treated with
1–10 mg/ml tunicamycin or the vehicle alone (DMSO) for the
time and the temperature indicated in the figure legends,
immunoprecipitated with the desired antibodies and resolved by
SDS-PAGE.
Surface Biotinylation
Pulse-chased (or non-labeled) transfected COS7 cells growing in
6 well plates (Nunc) were washed 3 times with complete PBS
(PBSc) containing 0.1 mM CaCl2 and 1 mM MgCl2, and they
were incubated for 30 minutes with Sulfo-NHS-Biotin in PBSc
(1.0 mg/ml, Pierce) at a temperature that blocks trafficking (4uC).
After two 30 min washes at 4uC, 100 mM L-lysine in PBSc was
added to block free biotin, cells were rinsed with 150 mM NaCl
and 50 mM Tris-HCl (pH 7.4) containing protease inhibitors
(0.4 mM PMSF and 4 mM pepstatin) and lysed by end-over-end
agitation for 30 minutes at 4uC with 1x lysis buffer (150 mM
NaCl, 50 mM Tris-HCl [pH 7.4], 5 mM EDTA, 1% Triton-X,
0.1% SDS, 0.25% deoxycholate sodium, 0.4 mM PMSF and
4 mM pepstatin). A portion of the lysate was saved for total protein
determination and the remainder was incubated with streptavidin-
agarose for 2 h at room temperature with rotary shaking. After
centrifugation, the supernatant was removed (except for an aliquot
- not biotinylated), and the agarose beads were washed 3 times
with 1x lysis buffer. The bound proteins (biotinylated) were eluted
with Laemmli buffer (65 mM Tris, 10% glycerol, 2.3% SDS,
100 mM DTT, 0.01% bromophenol blue) for 10 minutes at 75uC.
Samples were analyzed by SDS-PAGE, immunoblotting (Western
blot) and densitometry.
Electrophoresis and Western Blotting
Samples were subjected to SDS-PAGE using a 4% stacking gel
and 6% or 7.5% resolving gels. The samples were transferred to
nitrocellulose by semi-dry electrotransfer (Life Technologies Inc.:
1.2 mA/cm2 for 2 h) and the membranes were then blocked with
5% milk in PBS for 4 h at 25uC. The membranes were probed
overnight at 4uC with the desired primary antibody: anti-GLYT2
(1:1,000), anti-CNX (1:1,000) or anti-PERK (C33E10, 1:1,000,
Cell Signaling Technology Inc., Danvers, MA). After several
washes, the antibodies bound were detected with peroxidase
coupled anti-rat or anti-rabbit IgG respectively (1:6,000), which
were visualized by ECL (Amersham Corp.). Subsequently, the
antibodies were stripped from the membrane (Thermo Scientific)
and it was re-probed with anti-tubulin (1:3000; Sigma), which was
detected with peroxidase-coupled anti-rabbit IgG. The protein
bands were quantified by densitometry.
Inmunoprecipitation Assays
Transfected COS7 cells were washed twice with 20 mM N-
ethylmaleimide in PBS and solubilized for 15 min at 4uC in 1 ml
of 1% 3-((3-Cholamidopropyl) dimethylammonio)-1-propanesul-
fonic acid (CHAPS) in HEPES-buffered saline (HBS) buffer
(10 mM HEPES-NaOH [pH 7.4], 150 mM NaCl, 1 mM EDTA,
1% CHAPS, 0.4 mM PMSF and 4 mM pepstatin). The CNX-
GlyT2 complexes were also maintained in both Triton X-100 and
digitonin at the same concentration, although CHAPS displayed
the highest solubilization potency. The solubilized material was
centrifuged at 10,0006g for 15 min. A portion of the lysate was
retained (total protein, input or lysate) and the remainder was
incubated with 30 ml of 50% protein A or G cross-linked to
sepharose beads in lysis buffer (PAS or PGS: Sigma, St Louis, MO,
USA). The mixture was precleared by incubation for 30 min at
4uC with continuous rotation, the samples were centrifuged and
the supernatants were incubated for 2 hours at 4uC with 1.5 mg of
anti-GlyT2 [33] or anti-CNX antibody (Stressgen Biotechnologies
Corp., Victoria, Canada). Subsequently, 30 ml of beads were
added and the mixture was incubated for 1 h at 4uC with constant
rotation. The beads were washed 3 times with 0.5% CHAPS in
ice-cold HBS before adding SDS-PAGE sample buffer to each
sample (30 ml). The bound proteins were dissociated from the
beads by heating at 75uC for 15 min before SDS-PAGE
resolution. For sequential immunoprecipitation, the immunopre-
Figure 3. Expression of GlyT2 following CNX knockdown/overexpression. (A) COS7 cells were co-transfected with 0.5 mg of GlyT2 cDNA in
pCDNA3 and the indicated amount of control (HPRT) or CNX siRNA. At 48 h post-transfection, the cells were analyzed in Western blots (upper panel)
or assayed for glycine transport (open bars, left graph). The specific CNX d-siRNA reduced CNX protein levels by 62% (0.2 mg) and 85% (0.4 mg),
respectively, as compared with endogenous levels. Control d-siRNA increased total GlyT2 levels by 10% and 15%, respectively. Right graph: ratio of
mature (100 kDa) to immature (75 kDa) band at the different amounts of CNX siRNA transfected. The bands were detected with GlyT2 antibodies
against N- or C-terminal epitopes (Fig. S1). (B) COS7 cells were co-transfected with 0.5 mg of GlyT2 cDNA together with a CNX cDNA at the indicated
mass ratio (CNX:GlyT2). At 48 h post-transfection the cells were biotinylated (T = total transporter; N =non-biotinylated transporter; B = biotinylated
transporter, 3-fold the protein amount in T or N) or glycine transport was assayed (open bars, left histogram). Solid bars in the left histogram
represent total GlyT2 normalized to tubulin immunoreactivity. Verification of CNX overexpression by densitometry revealed the following increases at
increasing mass ratios: 0:1, 1-fold (endogenous CNX); 0.5:1, 1.8-fold; 4:1, 2.4-fold; 8:1, 9.3-fold; 10:1, 12.9-fold. Right graph: the ratio of the mature
(100 kDa) to immature (75 kDa) protein decreased with the amount of CNX expressed. Bars represent the S.E.M (n = 6). *p,0.05, **p,0.01,
***p,0.001 with respect to control (Student’s t-test).
doi:10.1371/journal.pone.0063230.g003
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cipitated proteins were eluted from the beads by adding 150 ml of
1% SDS in HBS at 75uC for 30 min and centrifuged. The
supernatant was diluted with 1.35 ml 1% CHAPS in HBS to
decrease the SDS concentration to 0.1% and transferred to a new
tube containing 1.5 mg of anti-GlyT2 antibody and incubated
overnight at 4uC. The immunocomplexes were bound to beads
and eluted as described above. Samples were subsequently
subjected to SDS-PAGE.
Figure 4. Characterization of GlyT2 N-glycan site mutants. (A) COS7 cells expressing the indicated GlyT2 N-glycosylation mutants were
biotinylated and processed as described in the Materials and Methods. (A) Lysates (6 mg, total transporter, left) or biotinylated protein (18 mg,
biotinylated transporter, right) were resolved by SDS-PAGE and analyzed in Western blots to detect GlyT2. Tubulin immunoreactivity was used as
a loading control. Immunoblots were quantified by densitometry. (B) Densitometry representing the proportion of mutant biotinylated transporter as
a percentage of the biotinylated fraction of wild-type GlyT2. (C) Densitometry of the Western blots expressing the fraction of mature transporter
(upper band) as a percentage of the total transporter for each mutant. (D,E) COS7 cells expressing the indicated GlyT2 N-glycosylation mutants were
assayed for glycine transport (as described in the Materials and Methods) in the presence of increasing concentrations of glycine from 1 to 1000 mM.
Kinetic data were fitted to hyperbolae and Vmax and Km parameters were calculated from the best fit. For wild-type GlyT2, Vmax = 1763.8 nmol gly/mg
prot/4 min and Km= 171620 mM. Bars represent the S.E.M (n = 3). *p,0.05, **p,0.01, ***p,0.001 with respect to wild-type GlyT2 (ANOVA with
Tukey’s post-hoc test).
doi:10.1371/journal.pone.0063230.g004
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siRNA Generation and Transfection
CNX mRNA silencing was achieved by generating and
transfecting CNX-specific small d-siRNA into COS7 cells as
indicated below. A 300-base pair CNX amplification product
(IMAGE number 2582119) flanked by a T7 promoter (RZPD,
German Resource Center for Genome Research) was transcribed
in vitro using the X-tremeGENE siRNA Dicer Kit (Roche)
following the manufacturer’s instructions. The resulting annealed
dsRNA was subsequently digested with recombinant Dicer
enzyme, and the digested RNA was purified and d-siRNA was
transfected into COS7 cells using the X-tremeGENE siRNA
Transfection Reagent (Roche) with 2.5 ml/0.2 mg d-siRNA.
Knockdown efficiency of the CNX-siRNA was assessed in
Western blots 48 h post-transfection and it was 85–90%. The
siRNA from hypoxanthine phosphoribosyltransferase (HPRT)
served as a control.
Glycine Transport Assays
The day before the assay, the cells transfected with pcDNA3
(control) and/or the cDNAs under study were seeded at 80%
confluence in 24 well plates (Nunc). The culture medium was then
removed. The cells were washed with PBS (137 mM NaCl,
0.9 mM CaCl2, 2.68 mM KCl, 1.47 mM KH2PO4, 0.49 mM
MgCl2, 7.37 mM Na2HPO4 [pH 7.4] and 10 mM glucose) and
tempered at 37uC. After a further 10 minute incubation at 37uC
with 250 ml of transport medium (2 ml/ml [2-3H]-glycine
[PerkinElmer Life Sciences], 1.6 TBq/mmol, isotopically diluted
to a concentration of 10 mM in PBS), the cells were washed with
750 ml PBS and lysed with 250 ml of 0.2 M NaOH. The protein
concentration was determined in aliquots taken from each well by
the Bradford method (Biorad) and [2-3H]-glycine was measured
by liquid scintillation (LKB 1219 Rackbeta). GlyT2 transport was
measured as the difference between glycine accumulation in
cDNA-transfected cells and that observed in mock-transfected
cells. Assays were performed in triplicate or quadruplicate.
Membrane Isolation
Cells were recovered with PBS 1 mM EDTA and by
centrifugation at 1,000 rpm for 5 minutes, resuspended in PBS-
EDTA and lysed mechanically by passing the sample 5 times
through a needle of 0.5 mm diameter. The lysate was cleared by
centrifugation (3,500 rpm for 10 minutes) and the supernatant was
collected. The pellet was resuspended in PBS-EDTA and passed 5
times through a needle of 0.3 mm diameter, a step that was
repeated twice more. The pellet was discarded and the superna-
tant collected in the 3 steps above was centrifuged at 18,000 rpm
for 45 minutes. The supernatant was discarded and the
membrane-enriched pellet was resuspended in a minimal volume
of PBS-EDTA. The protein concentration was determined by the
Bradford method and adjusted to 0.5 mg/ml.
Limited Proteolysis
Membranes (25 ml) from an enriched fraction obtained by
subcellular fractionation were incubated with 0–100 mg/ml of
Papain (Roche) and 0.8 mM DTT in a final volume of 50 ml PBS
for 15 minutes at room temperature (22uC). The digestion was
stopped by adding 5 mM E-64 (Roche) for 5 minutes on ice and
the sample was centrifuged for 90 min at 4uC and 14,000 rpm.
The supernatant was discarded and the pellet was resuspended in
Laemmli buffer and incubated for 20 minutes at 37uC. Finally,
samples were separated by SDS-PAGE and the proteins were
visualized by Western blot.
Data Analysis and Densitometric Quantitation
Protein bands visualized by ECL (Amersham) or by fluorogra-
phy were quantified in a GS-800 Calibrated Imaging Densitom-
eter using the BioRad Quantity One program with film exposures
in the linear range. Non-linear regression fits of experimental
transport data were performed using ORIGIN software (Microcal
Software, Northampton, MA). The bars represent the S.E.M. of
triplicate samples and the representative experiments shown were
repeated at least 3 times with comparable results.
Results
To better understand the requirements for the expression of
newly synthesized GlyT2 transporters at the plasma membrane,
we measured the kinetics of GlyT2 expression in COS7 cells by
[35S]methionine/cysteine pulse-chase assays, from which GlyT2
was immunoprecipitated with a specific antibody [33]. According
to the presence of N-glycans attached to GlyT2 at the cell surface
[29], electrophoretic separation of the transporter recovered from
cultured cells revealed a protein doublet composed of a glycosy-
lated surface and intracellular forms [29,34]. In our experimental
conditions, biosynthesized GlyT2 initially appeared as a 75 kDa
metabolic precursor with a half-life of about 1 hour, which then
gave rise to a 100 kDa mature transporter (Fig. 1A). The 100 kDa
mature protein was present at the plasma membrane and could be
labeled with the membrane-impermeant reagent NHS-SS-biotin.
The biotinylation of this band increased exponentially during the
first 2 hours, reaching a plateau at which it remained for more
than 20 hours, suggesting a half-life for this mature protein of over
24 hours (Fig. 1B).
We next employed carbohydrate modification to confirm the
glycosylation state of the 75 kDa precursor and to determine its
location within the secretory pathway (Fig. 1D, E). Complete
enzymatic removal of N-linked glycans with PNGase F from both
the 75 kDa and the 100 kDa forms after pulse-labeling and
subsequent immunoprecipitation yielded a 60-kDa band (Fig. 1D).
A protein of the same size was obtained from the 2 protein bands
upon treatment of the pulse-chased cells with the N-glycosylation
blocker tunicamycin, indicating that the 60 kDa form corresponds
to the deglycosylated protein core (Fig. 1C). In contrast to the
Figure 5. Effects of glucosidase and mannosidase inhibitors on CNX binding and GlyT2 maturation. (A) COS7 cells expressing GlyT2
were treated for 2 h with the vehicle alone (DMSO), 1 mg/ml tunicamycin, 1 mM castanospermine (cas), 1 mM deoxynojirimycin (dnj) or 1 mM
castanospermine plus 1 mM deoxynojirimycin (cas/dnj), and then pulse-labeled for 15 min with [35S]methionine/cysteine and chased for 30 min. The
cell lysates were then immunoprecipitated with a GlyT2 antibody or subjected to sequential immunoprecipitation with CNX and GlyT2 antibodies (as
described in the Materials and Methods) and resolved by SDS-PAGE. Right panel: densitometry of the fluorograms (n = 3) showing the percentage of
total GlyT2 precursor bound to CNX in each condition (6 S.E.M). (B) COS7 cells expressing GlyT2 were treated for 2 h with the vehicle alone (water),
1–50 mM castanospermine (upper graph) or 0.2–1 mM deoxynojirimycin (lower graph) and then glycine transport was assayed in the cells. (C) COS7
cells expressing GlyT2 were treated for 2 h with the vehicle alone (control), 1 mM castanospermine or 2 mM deoxynojirimycin and then pulse-labeled
for 15 min with [35S]methionine/cysteine, chased for the times indicated. The cell lysates were immunoprecipitated with GlyT2 antibody and analyzed
by SDS-PAGE. Lower graphs: densitometry. (D,E) The experimental conditions applied were as described in A and C, except the cells were treated with
1 mM deoxymannojirimycin (DXM) or 10 mM kifunensin (KIF). *p,0.05, **p,0.01, ***p,0.001 with respect to controls (Student’s t-test).
doi:10.1371/journal.pone.0063230.g005
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mature transporter, which was resistant to endoglycosidase H
(EndoH) digestion, the 75 kDa precursor was EndoH-sensitive at
all the time points assayed. This is to be expected for a protein
transported via the early secretory pathway. The amount of
EndoH-digested protein suggests total EndoH sensitivity, although
a general decrease in total GlyT2 labeling, probably due to some
contaminant protease activity, was also observed (Fig. 1E).
Moreover, the transporter was not sensitive to endoglycosidase
D at any time points assayed (data not shown). Taken together,
these data indicate that the 75 kDa immature form of GlyT2 is
likely to be an underglycosylated form located in the ER or cis
Golgi [35].
The ER is the site at which quality control of the glycoproteins
synthesized takes place, with the assistance of molecular chaper-
Figure 6. Co-immunoprecipitation of GlyT2 N-glycan mutants and CNX. COS7 cells expressing the indicated single (A), double (B) or
multiple (C) N-glycan mutants were pulse-labeled for 15 min with [35S]methionine/cysteine and chased for 30 min. The cell lysates were
immunoprecipitated with GlyT2 antibody or subjected to sequential immunoprecipitation with CNX and GlyT2 antibodies (as described in the
Materials and Methods) and analyzed by SDS-PAGE. Right panels: densitometric analysis of the fluorograms (n = 3) showing the percentage of total
GlyT2 precursor bound to CNX in each condition (6 S.E.M). *p,0.05 with respect to wild-type GlyT2 (ANOVA with Tukey’s post-hoc test).
doi:10.1371/journal.pone.0063230.g006
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ones such as calnexin (CNX) [36]. The 75 kDa GlyT2 precursor
co-immunoprecipitated with an antibody against CNX and its
immunodetection in Western blots was prevented by antigen
preadsorption with an excess of the GlyT2 fusion protein (GlyT2-
GST) previously used to generate the GlyT2 antibody [33]. These
observations confirmed the immunoprecipitated 75 kDa band to
be the transporter precursor (Fig. 2A). The co-immunoprecipita-
tion of GlyT2 and CNX also occurred in primary neurons in
which GlyT2 appeared as a lower molecular weight band that
overlapped with that of the precursor (Fig. 2B). However, GlyT2
did not immunoprecipitate with calreticulin in any of the
conditions assayed (Fig. 2A). We next measured the kinetics of
the GlyT2-CNX interaction by performing sequential immuno-
precipitation of GlyT2-expressing pulse-chased COS7 cells using
CNX and GlyT2 antibodies (Fig. 2C). The 75 kDa precursor
transiently associated with CNX to form a complex with a half-life
of about 60 min, which agreed with the onset of the expression of
the 100 kDa mature transporter, suggesting that CNX facilitates
GlyT2 biogenesis. The CNX-bound GlyT2 was deglycosylated by
PNGaseF, it was sensitive to Endo H and was Endo D resistant, as
expected of the GlyT2 precursor present in the ER or cis Golgi
(not shown). In agreement with a facilitatory role of CNX in
GlyT2 biogenesis, total expression of the transporter was sensitive
to the expression of the chaperone (Fig. 3). Knockdown of CNX in
COS7 cells using a specific RNAi reduced the total transporter
expression (as evident in Western blots) and decreased glycine
transport activity in a dose-dependent manner (Fig. 3A), indicating
that the low levels of remaining CNX limit GlyT2 synthesis.
Consequently, accumulation of the mature form of the transporter
was observed, resulting in a progressive increase in the mature
(100 kDa)/immature (75 kDa) ratio in steady state conditions.
This increase is not due to a differential recognition of the
immature protein by the used GlyT2 antibody, since the same
result was obtained with an antibody against the C-terminus of
GlyT2 (Fig. 3A and Fig. S1). Conversely, with an optimized co-
transfection protocol in COS7 cells we found that CNX over-
expression dramatically increased total GlyT2 expression and
glycine transport. Furthermore, in agreement with the increased
number of binding sites for the GlyT2 precursor following CNX
overexpression, we also detected an increased proportion of
immature transporter (Fig. 3B). Together, these results confirm
that GlyT2 biosynthesis is assisted by CNX.
We previously demonstrated that GlyT2 contains 4 N-glycan
chains attached to asparagines 345, 355, 360 and 366 in the
mature protein [29]. As a monovalent lectin, CNX has affinity for
monoglucosylated intermediaries but it can also associate via
protein-protein interactions [27,28]. We constructed various
mutants with deficiencies in single or multiple N-glycan acceptor
sites by substituting the asparagines 345, 355, 360 or 366 with
aspartates [29]. The single (N1, N2, N3 and N4) and double (N13,
N23, N24) mutants maintained a wild-type-like time course of
expression in [35S] pulse-chased COS7 cells (data not shown). The
onset of the appearance of the glycosylated protein in the singly
glycosylated triple mutants (N123, N134, N234) could not be
accurately determined in pulse-chased cells due to the small size of
the mature transporter close to the [35S]labeled immature
precursor. However, we observed a decrease in the amount of
biotinylated plasma membrane transporter (Fig. 4A–C) that
paralleled transporter activity (Fig. 4D,E). The Vmax of glycine
transport diminished progressively and the Km increased mark-
edly, reaching levels in the fully deglycosylated mutant (N1234)
that were 5-fold higher than those of the wild-type GlyT2. This
increase in Km was also observed when N-glycosylation mutants
were generated by replacing the asparagines with glutamines
rather than aspartates (data not shown), indicating that the sugar
rather than the charge removal caused the increase in Km. One
important exception in this series of mutants was the N4 mutant
(N366). Although its time course of expression was comparable
with that of the wild-type, this mutant exhibited slightly slower
mature protein synthesis (Fig. S2), reduced levels of total
biotinylated surface transporter (Fig. 4A,B), an increased pro-
portion of glycosylated versus total transporter (Fig. 4C), a lower
Vmax (Fig. 4D) and a higher Km than the other related mutants
(Fig. 4E). In addition, the glycosylated N4 band was of a lower
apparent weight than N2 and N3 (Fig. 4A), suggesting that either
the N-glycans attached to N366 have a greater molecular mass or
that their removal affects GlyT2 folding. We hypothesized that
some of the features displayed by the N4 mutant were sustained by
reduced binding to CNX (see below). We therefore further
investigated the factors that influence GlyT2 binding to the
chaperone.
Glucosidases I and II (GI and GII) give rise to monoglucosy-
lated CNX substrates [37]. Treatment of GlyT2-expressing COS
cells with the glucosidase inhibitors castanospermine and deox-
ynojirimycin resulted in a partial but consistent reduction in the
levels of CNX-bound transporter recovered by sequential im-
munoprecipitations (Fig. 5A). CNX binding was also sensitive to
low concentrations of tunicamycin, an inhibitor of N-glycosylation.
Moreover, glucosidase inhibition impaired glycine transport
activity (Fig. 5B) as a consequence of decreased transporter
maturation (Fig. 5C). By contrast, mannosidase inhibition did not
reduce the amount of CNX-bound GlyT2, although it fully
prevented the generation of the mature 100 kDa transporter
(Fig. 5D,E). The latter observation was expected as mannose
trimming is not required for the generation of CNX substrates but
it is necessary for the further processing of glycans in the Golgi
[28]. The increased specificity and membrane permeability of
mannosidase versus glucosidase inhibitors may explain the greater
efficiency of the former in preventing the expression of the mature
transporter [38]. The loss of sugar following mutagenesis also
Figure 7. CNX-binding and folding properties of the N-glycan-deficient GlyT2 mutant. (A) COS7 cells expressing the N1234 N-glycan-
deficient mutant were pulse-labeled for 15 min with [35S]methionine/cysteine and chased for the indicated time. The cell lysates were
immunoprecipitated with GlyT2 antibody or subjected to sequential immunoprecipitations with CNX and GlyT2 antibodies as described in the
Materials and Methods and resolved by SDS-PAGE. Lower graph: densitometry of the fluorograms (n = 2) showing the percentage of N1234 bound to
CNX in each condition (6 S.E.M). (B) The membrane enriched fraction from COS7 cells expressing GlyT2 or the N1234 N-glycan-deficient mutant
(12.5 mg) was digested for 15 min at 22uC with the concentrations of papain indicated as described in the Materials and Methods and analyzed in
Western blots probed with antibodies against the GlyT2 N-terminus. (C) COS7 cells expressing wild-type GlyT2 or the N1234 mutant were treated
with the vehicle alone (-) or 10 mg/ml tunicamycin (+) for 3 h at 37uC, pulse-labeled for 15 min with [35S]methionine/cysteine and then chased for
90 min at the temperature indicated. The cell lysates were immunoprecipitated with GlyT2 antibody or subjected to sequential immunoprecipitation
with CNX and GlyT2 antibodies as described in the Materials and Methods and resolved by SDS-PAGE. Right panels: densitometry of the fluorograms
(n = 3) showing the percentage of total GlyT2 precursor bound to CNX in each condition (up) and the total synthesized transporter (down). Bars
represent the S.E.M. (n = 3). *p,0.05, **p,0.01 with respect to wild-type control (Student’s t-test). (D) The experimental conditions applied were as
described in Figure 3B except that cells expressed the N1234 mutant and CNX overexpression was achieved by co-expressing CNX and N1234 at
ratios of 0:1, 4:1 and 8:1. *p,0.05, **p,0.01, ***p,0.001 with respect to the wild-type control (Student’s t-test).
doi:10.1371/journal.pone.0063230.g007
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hampered the interaction with CNX measured after a 15-min
pulse and a 30-min chase. However, these experiments revealed
no correlation between glycan removal and CNX binding. Indeed,
depending on the single or multiple N-glycan-deficient mutant
chosen, 60–80% of the CNX binding observed in the wild-type
was obtained (Fig. 6A,B). Moreover, the removal of 3 or 4 N-
glycosylation sites did not further impair CNX interaction. In fact,
a considerable amount of N-glycosylation-deficient GlyT2 mutant
was bound to CNX and recovered by sequential immunoprecip-
itation (Fig. 6C), suggesting that the association of GlyT2 with
CNX is mediated by interactions involving both sugars and
polypeptides. Accordingly, the reduced CNX binding exhibited by
the N4 mutant was possibly due to the involvement of N366 in
CNX binding or to an alteration in the conformation of GlyT2
following N-glycan removal.
The behavior of the N1234 mutant, which lacks N-glycan
acceptor sites, provided further evidence of the involvement of
protein-protein interactions in GlyT2 binding to CNX (Figs. 4 and
7). In contrast to wtGlyT2, which associated transiently with CNX
(Fig. 2C), the mutant engaged in a more persistent interaction with
the chaperone, as revealed by sequential immunoprecipitation of
pulse-chased cells with CNX and GlyT2 antibodies (Fig. 7A). This
finding was consistent with the reduced surface expression and
Vmax of glycine transport shown by this mutant (Fig. 4A,B,D), and
suggests that the unglycosylated transporter does not easily pass
CNX quality control, an ER check point for newly synthesized
glycoproteins [39]. This longer lasting binding may reflect an
alteration to the 3-dimensional structure of the mutant that is
detected by CNX. Indeed, the mutant displayed increased
proteolytic sensitivity in a limited proteolysis experiment using
the wild-type and N1234 mutant and increasing concentrations of
papain, such that low molecular weight proteolytic fragments (36,
34, 30 and 18 kDa) that could be detected with an antibody
against the N-terminal region of GlyT2 were produced at different
protease concentrations (Fig. 7B). This may be indicative of
misfolding in the mutant, although glycan-mediated protection
from proteolysis is also possible.
As well as inhibiting N-glycosylation, tunicamycin may also
trigger the unfolded protein response (UPR) and therefore act as
a misfolding agent when used at high concentrations or long
incubation times [40]. Hence, we performed pulse-chase experi-
ments in the presence of this inhibitor with longer chase times
(90 min) and at different temperatures (Fig. 7C). In the presence of
high concentrations of tunicamycin, the association of wild-type
GlyT2 to CNX was enhanced at 37uC and to a much lesser extent
at 45uC, suggesting that this association is enhanced by
tunicamycin-induced unfolding. The effect of tunicamycin was
less evident at 45uC as both tunicamycin and high temperature
treatment trigger general unfolding (Fig. 7C, upper histogram). By
contrast, the N1234 mutant displayed greater CNX binding in all
the conditions assayed, and its association to CNX was insensitive
to tunicamycin or the increase in temperature. The same pattern
was observed in assays using thapsigargin, another inducer of UPR
(data not shown). Moreover, the total amount of wild-type
transporter synthesized at 37uC was reduced in the presence of
tunicamycin, while that of the mutant was tunicamycin-insensitive.
As expected, there was a general reduction in total protein
synthesis at 45uC (Fig. 7C, lower histogram). These results strongly
suggest that the 3-dimensional structure of the N1234 mutant
lacking sugar chains is altered, consistent with its proteolytic
pattern and with the dramatic increase in the Km for glycine
transport shown by this mutant (Fig. 7B and 4E).
To determine whether CNX can act as a bona-fide chaperone
independently of its lectin activity, we investigated the effect of
CNX overexpression in cells expressing the N1234 mutant using
the experimental conditions shown in Fig. 3B for wtGlyT2
(Fig. 7D). In agreement with the effect of CNX on the wild-type
GlyT2, total expression of the mutant and its glycine transport
were enhanced by CNX overexpression, albeit to a lesser extent
(Fig. 7D, left histogram). Conversely, surface expression of the
mutant transporter was reduced by overexpressing the chaperone
(Fig. 7D, right histogram), suggesting that it was more efficiently
folded although less of the mutant transporter reached the plasma
membrane. These findings suggest that CNX can discriminate
between different conformational states in a glycan-independent
manner and select the most functionally competent structure
required.
The long-term binding of the glycosylation-deficient mutant to
CNX suggests that it fails to progress past a quality control check
point. This may result in the transporter being sent for
proteasomal degradation, the ultimate fate of deficiently-folded
membrane proteins [41–43], or it may be resolved by correct
folding and subsequent progression through the secretory path-
way. Treatment of N1234-expressing COS7 cells with the
lysosome inhibitor chloroquine, or with high concentrations of
the proteasome inhibitors MG132 and lactacystin (data not
shown), resulted in comparable increases in the amount of mutant
transporter (Fig. 8A). This may indicate that the mutant uses both
lysosomal and proteasomal pathways for degradation. However,
the same treatments applied to wild-type cells expressing GlyT2
produced opposite effects: while treatment with the lysosome
inhibitor chloroquine augmented the mature (100 kDa) trans-
porter, proteasome inhibition reduced the amount of mature
transporter (Fig. 8B). In addition, a band of ,60 kDa visibly
augmented in immunoprecipitates from cells treated with protea-
some inhibitor. The apparent molecular weight of this band
coincided with that of the deglycosylated protein core (Fig. 1),
suggesting that it represents an early arrested form of the
transporter. This raises the possibility that proteasome inhibition
in our experimental conditions induced ER stress and affected
general ER protein folding.
To further investigate this possibility we studied the effect of
increasing MG132 concentrations on glycine transport by
wtGlyT2, the N1234 mutant and a control protein (GlyT1). All
3 transporters were similarly sensitive, suggesting that off-target
secondary effects of proteasome inhibition may produce a general
folding defect (Fig. 8C). Indeed, the phosphorylated form of
protein kinase-like endoplasmic reticulum kinase (PERK), a well-
Figure 8. Degradation of GlyT2. (A,B) COS7 cells expressing the N1234 mutant or wild-type GlyT2 were treated with 0.1 mM chloroquine (CQ),
50 mM MG132 (MG) or the corresponding vehicles (water and DMSO, respectively) for the times indicated, resolved by SDS-PAGE and GlyT2 was
analyzed in Western blots. Densitometry (n = 2–4) is shown in the histograms in A and B. *p,0.05, **p,0.01 with respect to control at the
corresponding time points (Student’s t-test). (C) COS7 cells expressing wtGlyT2, N1234 or a control protein (GlyT1) were treated with vehicle or
MG132 for 16 h at the concentrations indicated and glycine transport was then assayed in the cells. Bars represent the S.E.M. (n = 3). ***p,0.001 with
respect to control (Student’s t-test). (D) COS cells were treated with vehicle or 5 mM MG132 for the times indicated and then resolved in SDS-PAGE
and PERK was analyzed in Western blots. Tubulin immunoreactivity was used as a loading control in A, B and D. (E) COS7 cells expressing the N1234
mutant or wild-type GlyT2 were treated for 5 hours with 0.1 mM chloroquine (CQ), 50 mM MG132 (MG) or the corresponding vehicle solutions (water
and DMSO, respectively), biotinylated and GlyT2 was analyzed in Western blots. *p,0.05 with respect to wild-type control (Student’s t-test).
doi:10.1371/journal.pone.0063230.g008
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established ER stress marker that is activated during UPR and that
attenuates mRNA translation by phosphorylating eIF2a [44], was
already visible when the cells were treated for 3 h with a low
concentration of MG132 (5 mM; Fig. 8D). Thus, a clearly involved
degradation pathway for both wtGlyT2 and the N1234 mutant
appears to be the lysosome, as both seem to accumulate in the
presence of lysosome inhibitors (Fig. 8E). However, this effect was
more evident for the wild-type especially over longer chase times
(Fig. S3), leading us to consider a contribution of the proteasome
in the degradation of the mutant.
Discussion
According to the validated LeuTAa homology model for the
SLC6 family of sodium- and chloride-dependent transporters, the
plasma membrane GlyT2 has 12 transmembrane domains (TM)
oriented such that TMs 1–5 are positioned in an antiparallel
conformation relative to TMs 6–10 [13–15]. While resolving the
crystal structure of the prokaryote transporter has furthered our
understanding of the underlying protein structure significantly, the
biosynthesis of polytopic plasma membrane proteins like GlyT2
and the role of the N-glycans attached to its EL2 remain poorly
understood. Nascent GlyT2 is translocated to the lumen of the ER
and oligosaccharide moieties are co-translationally attached to 4
EL2 asparagines in N-glycosylation consensus sequences (N345,
N355, N360 and N366) [29]. CNX/CRT retains glycoproteins in
the ER by re-binding to the lectin site until a folded conformation
of the substrate is achieved. Properly folded glycoproteins are
incorporated into transport vesicles and exported to the Golgi,
while terminally misfolded glycoproteins that persist in CNX/
CRT cycles are targeted for degradation by the ER-associated
degradation (ERAD) pathway [28,36].
Our electrophoretic analysis of GlyT2-expressing cells revealed
a 75 kDa precursor that disappeared as the chase times following
[35S]-labeling increase. This protein represents the ER precursor
that has received the initial 14-sugar chain from dolichol and
carbohydrate removal with PNGase F or tunicamycin yielded
a 60 kDa protein core. This is smaller in size than the protein
predicted by summing the molecular weights of the individual
amino acid residues (78.9 kD), although packing of the protein
fraction may account for this weight difference, as previously
described for other related transporters [45]. At longer chase
times, the fully glycosylated transporter appeared as a 100 kDa
diffuse band, which may contain a mixture of glycosylated species
in different states of trimming. We investigated several aspects of
GlyT2 biogenesis in which CNX plays a facilitatory role. By
performing sequential immunoprecipitation with CNX followed
by GlyT2 antibodies, we captured the pulse-labeled 75 kDa CNX-
bound precursor in the ER. The CNX-bound precursor reached
maximal levels immediately after the pulse, before the appearance
of the mature 100 kDa transporter, and then decayed to basal
levels. As expected for CNX-assisted biogenesis, GlyT2 was very
sensitive to CNX concentrations, and siRNA-mediated CNX
knockdown in GlyT2-expressing cells reduced membrane expres-
sion and transport function by limiting the amount of the available
precursor. These results are in good agreement with the phenotype
of CNX knockout mice, which die after 4 weeks due to the
inability of CRT to fully substitute CNX activity [46]. We detected
no GlyT2 binding to CRT in any of the conditions assayed, which
included a range of different detergents and chase times. On the
other hand, optimizing the co-transfection protocol to use low
levels of transfected cDNA and prevent competition for the cell
translation machinery, we demonstrated that the access of GlyT2
to the membrane was facilitated dramatically following CNX
overexpression. CNX made possible the maturation of a greater
proportion of immature transporter and increased levels of
transporter at the cell surface and thus transport activity. These
results are in good agreement with earlier studies of other SLC6
transporters [47], and strongly support the role of CNX as
a chaperone in GlyT2 biogenesis.
GlyT2 binding to CNX is mediated by glycans and protein-
protein interactions, as revealed by disruption of transporter
binding with pharmacological treatments and through the
behavior of GlyT2 mutants lacking N-glycan acceptor sites. GlyT2
binding to CNX is sensitive to GI and GII inhibitors. Deoxinojir-
imycin is a more potent GII inhibitor than castanospermine, yet
the latter inhibits the activity of both GI and GII [48,49]. The
differential effect of these inhibitors on GlyT2 biosynthesis may be
linked to the crucial role of GI in rapid glucose trimming after
glycan addition or the modulation of GII activity by neighboring
N-glycans, which may attenuate the inhibition of GlyT2 [36,37].
However, the cell permeability of both these compounds is poor,
and although IC50 values in the low micromolar range have been
measured in cell-free systems, these values increase by several
orders of magnitude in cell cultures [38]. This may explain why
these glucosidase inhibitors exhibited variable effects and why high
concentrations were required to prevent GlyT2 maturation.
However, even using concentrations in the high mM range, we
were unable to fully prevent GlyT2 binding to CNX, indicating
that CNX binding requires polypeptide- as well as lectin-based
interactions [36,39].
The binding of GlyT2 to CNX was also sensitive to the removal
of single or multiple N-glycan sites, although it increased most
when all N-glycan binding sites were removed. This is consistent
with the hypothesis that initial binding to calnexin requires
monoglucosylated N-linked oligosaccharides until the mature
protein conformation is achieved, although the retention of bound
proteins is not mediated by the glycans but by polypeptide motifs
[50,51]. Furthermore, for GII to generate the monoglucosylated
oligosaccharide in mammalian cells, at least 2 oligosaccharide
chains on the substrate glycoprotein are required [37]. The
removal of multiple glycosylation sites may alter the protein
conformation and unmask unfolded peptide regions that are
detected by CNX, thereby increasing binding. This may be due to
a chaperone-independent pro-folding effect of N-glycosylation, as
reported for the cystic fibrosis transmembrane regulator [52]. We
previously demonstrated that PNGase F treatment of the purified
and reconstituted GlyT2 impairs glycine transport, probably due
to the anomalous conformation of the deglycosylated protein [29].
In the present study we show that the GlyT2 N1234 mutant,
which lacks all 4 N-glycan acceptor sites, exhibits anomalous
folding as revealed by differential papain and pronase (not shown)
proteolysis patterns. Accordingly, this mutant displays deficient
glycine transport in functional assays, as revealed by a low Vmax
and high Km. Moreover, membrane expression of the mutant was
significantly impaired, while its binding to CNX was increased,
long-lasting and temperature-independent. The glycan bound to
N366 may crucially contribute to the N1234 phenotype, as the
phenotype of the N4 mutant (which lacks the N366-linked glycan)
shares several features with that of the N1234 mutant. The present
findings point to a lectin-independent chaperone activity of CNX
on GlyT2, as inferred by its interaction with the N1234 mutant.
Co-expression of CNX and N1234 rescued the mutant activity,
although not the surface transporter, suggesting that CNX
selectively facilitates the surface expression of the more competent
conformational state in a glycan-independent manner.
The final degradation of GlyT2 and the N1234 mutant
transporter occurs via the lysosomal pathway. The greater increase
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in the amount of mature transporter observed for the wild type in
the presence of lysosomal inhibitors may indicate the existence of
more than one degradation pathway for the mutant. However,
given the side effects produced by proteasome inhibition, it
remains unclear whether the mutant is more prone to proteasomal
degradation. In summary, we describe some of the processes
involved in GlyT2 biogenesis in the early secretory pathway,
including CNX assistance and binding interactions, and we reveal
a key role for CNX in the selection of functionally-competent
GlyT2 folding intermediates. In the light of this framework, it may
now be possible to decipher the effects of hyperekplexia mutations
on the plasma membrane expression of newly synthesized GlyT2
transporters.
Supporting Information
Figure S1 GlyT2 immunodetection with antibodies
against N-terminal and C-terminal epitopes. COS7 cells
expressing wt-GlyT2 or GlyT2 N-terminal (DN-GlyT2) or C-
terminal (DC-GlyT2) deletion mutants were lysed and subjected to
Western blot with antibodies against GlyT2 N-terminus (Nt-
GlyT2 Ab) or C-terminus (Ct-GlyT2 Ab). DC-GlyT2 mutant lacks
last 53 amino acids in the GlyT2 C-terminus. DN-GlyT2 mutant
lacks first 140 N-terminal amino acids of GlyT2 (Poyatos et al.,
2000 Molecular and Cellular Neuroscience 15, 99–111). Tubulin
immunoreactivity was used as a loading control.
(TIF)
Figure S2 Time course of expression of N4 mutant.
COS7 cells expressing wtGLYT2 or the N366D (N4) mutant were
pulse-labeled for 15 min with [35S]methionine/cysteine, chased
for the indicated times, immunoprecipitated with GlyT2 antibody
and resolved in SDS-PAGE. (A) Kinetics of expression of total
synthesized protein. (B) Densitometric analysis of the fluorogra-
phies representing labeled bands as a percentage of total
synthesized protein.
(TIF)
Figure S3 Long term lysosomal degradation of GlyT2.
COS7 cells expressing GlyT2 were treated with vehicle or 0.1 mM
chloroquine (CQ) during 1 h and then pulse-labeled for 15 min
with [35S]methionine/cysteine, chased for the indicated times in
the absence or presence of the inhibitor, immunoprecipitated with
GlyT2 antibody and resolved in SDS-PAGE. Histograms:
densitometric analysis of the fluorographies (n = 2–4). Significantly
different from the control at the corresponding chase time:
*p,0.05 and **p,0.01 in Student’s t-test.
(TIF)
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